Bank Nifty Option Tip

If You are Looking to Trade Intraday Bank Nifty option with twin target and make upto 150-300 points; then our Bank Nifty option tips is ideal for you as it provide Large Targets and Small Stop Loss. The aim is to make upto Rs 3750-7500 by trading in Bank Nifty Options by employing just Rs 10,000-20k capital. Click on Image or Post Title to Read More.

rocket call

Latest Video Reviews by Clients

You can have a look at the Video Reviews provided by our ongoing current clients regarding Indian-Share-Tips.Com Services to include Bank Nifty Option Tip. You must have a look to know about their satisfaction level, profit generated and complaints if any. Click on Image or Post Title to Read More.

Bank Nifty Tips which gets You Profit

Awards and Recognition

An award is something which is awarded based on Merit. Awards & Recognition are a must in Life as it provides the necessary vigour to keep progressing ahead in Life. Awards do not only acknowledge success; they recognise many other qualities: ability, struggle, effort and, above all, excellence. This is the reason that for past so many Years we have been adored as a Stock Market Tips Provider & we are at the 'Pinnacle' in this field. Check out our Awards by clicking on Image or Post Title Now!!

Best share market tips provider award in India

Jackpot Bank Nifty Option Tip

If You are Looking to Trade Intraday Bank Nifty option with Single Target and make 150-300 points; then our Bank Nifty option tips is best for you as it provide Large Targets and Small Stop Loss. The aim is to make Rs 3750-7500 almost daily by trading in Bank Nifty Options by employing just Rs 10,000 capital. Your profit is assured as we trade with "NO Loss Strategy". Click on Image or Post Title to Read More.

rocket call

Latest Video Reviews by Clients

You can have a look at the Video Reviews provided by our ongoing current clients regarding Indian-Share-Tips.Com Services to include Bank Nifty Option Tip. You must have a look to know about their satisfaction level, profit generated and complaints if any. Click on Image or Post Title to Read More.

Bank Nifty Tips which gets You Profit

Awards and Recognition

An award is something which is awarded based on Merit. Awards & Recognition are a must in Life as it provides the necessary vigour to keep progressing ahead in Life. Awards do not only acknowledge success; they recognise many other qualities: ability, struggle, effort and, above all, excellence. This is the reason that for past 22 Years we have been christined as Best Stock Market Tips Provider & we are at the 'Top' in this field. Check out our Awards by clicking on Image or Post Title Now!!

Best share market tips provider award in India

Pharma Sector Latest Update

Through this post we will undertake a quality check on the pharma sector and remember to read the comments below this post where latest content will be updated.

Pharma

Dicey near term, stay selective; long-term outlook positive

Q1FY2016 result expectations

Consecutive quarter of muted revenue growth: For Q1FY2016, most of the pharmaceutical players in our universe are expected to show a reasonable performance mainly due to a high-base effect, adverse cross-currency movement and fewer product approvals for the regulated markets. Divi’s Laboratories (Divi’s Lab; strong growth in contract manufacturing), Glenmark Pharmaceuticals (Glenmark Pharma; the US market saw seven abbreviated new drug application [ANDA] approvals in this quarter, so revenue stream may be better) and Torrent Pharmaceuticals (Torrent Pharma; a strong growth in Europe and Latin America) are likely to see a robust growth as compared with other companies. Whereas in the case of Sun Pharmaceutical Industries (Sun Pharma), the consolidation of Ranbaxy Laboratories (Ranbaxy) has resulted into higher growth (Sun Pharma result is not comparable on a Y-o-Y basis).

Earnings likely to consolidate, unlike past quarter no exclusive products: On an aggregated basis, the net sales of our pharma universe are expected to post a 4% growth, excluding Sun Pharma (including Sun Pharma, a 10% decline) on the back of an 8% growth in the domestic business and a 15% growth in the exports business. The operating profit margin is likely to contract by 478 basis points YoY while the net profit of the universe is likely to remain flat YoY for Q1FY2016 (including Sun Pharma the decline will be 10% YoY). The profit growth for the quarter will be led by Cadila Healthcare, Divi’s Lab, Glenmark Pharma and Cipla, while Lupin, Ipca Laboratories and Torrent Pharma will see a decline in profit.

Outlook

Issues in near term but a healthy growth outlook for long term: The past few quarters have seen a fewer number of product approvals in the USA, as the US Food and Drug Administration (USFDA) has been busy overhauling the drug review process. Meanwhile, the ANDA filings by the generic players kept piling up and currently, on an average, nearly 40% of the ANDAs filed are yet to be approved by the USFDA. This has moderated the growth in the US market (the US market is the largest contributor to the revenues of our universe) for most of the players. However, we expect a large chunk of the pending ANDAs to unfold in the next few quarters and that will help revive the growth rates. Also, the growth is likely to be driven by the domestic market, which is witnessing a robust volume growth, and the introduction of new drugs. Therefore, while we are positive on the long-term prospects of the sector, a few of the front-line players may see headwinds in the short term.

Valuation

Relying on the long-term prospects, most of the pharma companies have been successively re-rated over the past few quarters and that has led most of the front-line players to trade at a significant premium to their respective historical average multiples. On an aggregated basis, our pharma universe is trading at 27x its FY2016E earnings (vs 15x Sensex earnings) as compared with its historical average of 14-20x (on one-year forward earnings basis). However, we expect the premium to sustain due to an improving product profile and increasing reach of the Indian pharma companies. We advise staying selective in this space.

Preferred picks for this earnings season: Cadila Healthcare, Cipla and Divi’s Laboratories

Subscribe for free email updates to get daily free stock market tips and make money like professionals.

Jackpot Bank Nifty Option Tip

Jackpot Bank Nifty Option tip, as the name suggests has the potential to get you more money Profit as it is not the number of tips one trades; but it is the accuracy of a single tip which has the potential to help you realise your financial dreams. This tip is a value for money for all i.e whether one can see the trading terminal or not or is dealing through a broker on phone at BSE, NSE or in F&O. Thus you are on a correct path of making money every day with single daily accurate tip. Click on Image or Post Title to Read More.

Bank Nifty Prediction

Latest Video Reviews by Clients

You can have a look at the Video Reviews provided by our ongoing current clients regarding Indian-Share-Tips.Com Services to include Bank Nifty Option Tip. You must have a look to know about their satisfaction level, profit generated and complaints if any. Click on Image or Post Title to Read More.

In

Awards and Recognition

An award is something which is awarded based on Merit. Awards & Recognition are a must in Life as it provides the necessary vigour to keep progressing ahead in Life. Awards do not only acknowledge success; they recognise many other qualities: ability, struggle, effort and, above all, excellence. This is the reason that for past 22 Years we have been christined as Best Stock Market Tips Provider & we are at the 'Top' in this field. Check out our Awards by clicking on Image or Post Title Now!!

Best share market tips provider award in India

 
Chart> Nifty A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9